JP2010540446A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540446A5
JP2010540446A5 JP2010525937A JP2010525937A JP2010540446A5 JP 2010540446 A5 JP2010540446 A5 JP 2010540446A5 JP 2010525937 A JP2010525937 A JP 2010525937A JP 2010525937 A JP2010525937 A JP 2010525937A JP 2010540446 A5 JP2010540446 A5 JP 2010540446A5
Authority
JP
Japan
Prior art keywords
composition
decrease
composition according
caused
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010525937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540446A (ja
Filing date
Publication date
Priority claimed from US11/858,200 external-priority patent/US20080146497A1/en
Application filed filed Critical
Publication of JP2010540446A publication Critical patent/JP2010540446A/ja
Publication of JP2010540446A5 publication Critical patent/JP2010540446A5/ja
Pending legal-status Critical Current

Links

JP2010525937A 2007-09-20 2008-09-18 シクロスポリン組成物 Pending JP2010540446A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/858,200 US20080146497A1 (en) 2006-07-25 2007-09-20 Cyclosporin Compositions
PCT/US2008/076756 WO2009099467A2 (en) 2007-09-20 2008-09-18 Cyclosporin compositions

Publications (2)

Publication Number Publication Date
JP2010540446A JP2010540446A (ja) 2010-12-24
JP2010540446A5 true JP2010540446A5 (enExample) 2011-11-10

Family

ID=39528114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010525937A Pending JP2010540446A (ja) 2007-09-20 2008-09-18 シクロスポリン組成物

Country Status (12)

Country Link
US (1) US20080146497A1 (enExample)
EP (1) EP2190407B1 (enExample)
JP (1) JP2010540446A (enExample)
KR (1) KR20100091946A (enExample)
CN (1) CN101835463A (enExample)
AU (1) AU2008349774A1 (enExample)
BR (1) BRPI0816995A2 (enExample)
CA (1) CA2700182A1 (enExample)
IL (1) IL204614A0 (enExample)
MX (1) MX2010003045A (enExample)
RU (1) RU2010112472A (enExample)
WO (1) WO2009099467A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
MX2010003364A (es) 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
WO2010127301A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Method of treating allergic conjunctivitis with cyclosporin compositions
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
RU2014129268A (ru) * 2011-12-16 2016-02-10 Аллерган, Инк. Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
FR2988297B1 (fr) * 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
EP3169308B1 (en) * 2014-07-18 2021-01-27 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
RU2762767C1 (ru) * 2020-09-15 2021-12-22 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Министерства здравоохранения Российской Федерации Способ определения тактильной чувствительности роговицы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
EP1301210A2 (en) * 2000-07-14 2003-04-16 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
PL1904056T3 (pl) * 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法,組合物及套組

Similar Documents

Publication Publication Date Title
JP2010540446A5 (enExample)
Zhu et al. Broad-spectrum antiviral agents
RU2010112472A (ru) Композиции циклоспорина
JP2020502197A5 (enExample)
JP2014516954A5 (enExample)
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
CN102066402B (zh) 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物
KR20180037185A (ko) 광범위의 항감염성 펩티드
Jose et al. A cationic peptide, TAT-Cd0, inhibits herpes simplex virus type 1 ocular infection in vivo
Moerdyk-Schauwecker et al. Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27
JP5686454B1 (ja) コンタクトレンズ装着用液剤およびそれを用いたコンタクトレンズの屈折率向上方法
JP2018536638A5 (enExample)
CN104147162B (zh) 风湿止痛液及其使用方法
CN101491245A (zh) 一种含林蛙抗菌肽的消毒制剂及其制备方法和应用
CN108815141A (zh) 抗菌肽膜剂及其制备方法与应用
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
KR20110104367A (ko) 무보존제 안과용 조성물
Daelemans et al. Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle
JP2019525923A5 (enExample)
Zarei-Ghanavati et al. Acute Klebsiella pneumoniae interface keratitis after deep anterior lamellar keratoplasty.
Bravo et al. A model of human cytomegalovirus infection in severe combined immunodeficient mice
JP2016540799A5 (enExample)
CN105832722B (zh) 化合物pacma31在制备抗丙肝病毒感染药物中的应用
CA3087137A1 (en) Herbal extracts for treatment of herpesvirus infections
RU2018128737A (ru) Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов